SHORT CURRICULUM VITAE
EITAN YEFENOF, PH.D.
BORN:
September 26, 1948, Tel-Aviv, Israel
MARITAL STATUS:
Married, two children
CITIZENSHIP:
Israeli
MILITARY SERVICE:
IDF, 1966-1969
ACADEMIC BACKGROUND:
1972
B.Sc. in Microbiology and Biochemistry, Hebrew
University, Jerusalem, Israel.
1978
Ph.D. in Tumor Immunology, Karolinska Institute,
Stockholm, Sweden.
1978-1980
Postdoctoral studies, Hebrew University, Deptartment of
Immunology, Faculty of Medicine, Jerusalem, Israel.
ACADEMIC POSITIONS:
1975-1978
Research Fellow, Department of Tumor Biology,
Karolinska Institute, Stockholm, Sweden.
1978-1981
Instructor, Department of Immunology, Hebrew University,
Jerusalem, Israel.
1981-1984
Lecturer, Department of Immunology, Hebrew University,
Jerusalem, Israel.
1984-1985
Visiting Scientist, Department of Microbiology, University
of Texas Southwestern Medical Center, Dallas, Texas.
1985-1990
Senior Lecturer, Department of Immunology, Hebrew
University, Jerusalem, Israel.
1991-1992
Visiting Professor, Department of Microbiology, University
of Texas Southwestern Medical Center, Dallas, Texas.
1991-1997
Associate Professor, Department of Immunology, Hebrew
University, Jerusalem, Israel.
1996-2006
Director, Department of Immunology, Hebrew University,
Jerusalem, Israel
1996-present
Chairman, Lautenberg Center of Immunology and Cancer
Research, Hebrew University, Jerusalem, Israel
1997-present
Full Professor, Department of Immunology, Hebrew
University, Jerusalem, Israel
2001-2004
President, Israel Immunological Society
PUBLICATION LIST
EITAN YEFENOF
Yefenof, E. and Klein, G. Antibody redistribution of normal and tumor
associated surface antigens. Exp. Cell Res. 88:217-224, 1974.
1.
Killander, D., Yefenof, E. and Klein, E. Antibody induced redistribution of
surface antigens is independent of the amount of antigen and the cell cycle
position. Exp. Cell Res. 89:413-415, 1974.
2.
Klein, E., Nilsson, K. and Yefenof, E. A Burkitt lymphoma derived line with
cell surface IgG. Clin. Immunol. Immunopath. 3:575-583, 1975.
3.
Jondal, M., Klein E. and Yefenof, E. Rosette formation between peripheral Tlymphocytes and lymphoblastoid B cell-lines. Scan. J. Immunol. 4:259-266,
1975.
4.
Yefenof, E. and Klein, G. Difference in antibody induced redistribution of
membrane IgM in EBV genome free and EBV positive human lymphoid cells.
Exp. Cell. Res. 99:175-178,1976.
5.
Jondal, M., Klein, G., Oldstone, M.B.A., Bokish, V. and Yefenof, E.
Association between complement and EBV receptors on human lymphoid
cells. Scan J. Immunol. 5:401-410, 1976.
6.
Klein, E., Neuman, H., Steinitz, M. and Yefenof, E., Epstein- Barr Virus (EBV)
determined characteristics in lymphoid cells Comparative leukemia research
1975. Bibl. Haemt. No. 43, Eds. J. Clemmesen and D.S. Yohn, pp. 13-18,
Karger, Basel, 1976.
7.
Yefenof, E., Witz, I.P. and Klein, E. Interaction of antibody and cell surface
localized antigen. Int. J. Cancer 17:633-639, 1976.
8.
Yefenof, E., Klein, G., Jondal, M. and Oldstone, M.B.A. Two color
immunofluorescence studies on the association between EBV receptors and
complement receptors on the surface of lymphoid cell lines. Int. J. Cancer
17:693-700, 1976.
9.
Yefenof, E., Witz, I.P. and Klein, E. The fate of IgM and of anti IgM on
antibody coated Daudi cells. In: Leukocyte membrane determinants
regulating immune reactivity, Eds. V.P. Eijsvoogel, D. Roos and W.P.
Zeijlemaker, pp. 109, Academic Press, Inc. 1976.
10.
Yefenof, E., Klein, G., Ben-Bassat, H. and Lundin, L. Differences in the ConA induced redistribution and agglutination patterns of EBV genome free and
EBV carrying human lymphoma lines. Exp. Cell. Res. 108:185-190, 1977.
11.
Yefenof, E., Klein, G. and Kvarnung, K. Relationships between complement
activation complement binding and EBV absorption of human hematopoietic
cell lines. Cell. Immunol. 31:225-233, 1977.
12.
Yefenof, E. and Klein, G. Membrane receptor stripping confirms the
association between EBV receptors and complement receptors on the
surface of human B lymphoma lines. Int. J. Cancer 20: 347-352, 1977.
13.
Fenyo, E.M., Yefenof, E., Klein, E. and Klein, G. Immunization of mice with
syngeneic Moloney lymphoma cells induces separate antibodies against
virion envelope glycoprotein and virus induced cell surface antigen. J. Exp.
Med. 146:1521-1533, 1977.
14.
Yefenof, E., Bakacs, T., Einhorn, L., Ernberg, I. and Klein, G. Epstein-barr
Virus (EBV) receptors, complement receptors and EBV infectability of
different lymphocyte fractions of human peripheral blood. I. Complement
receptor distribution and complement binding by separated lymphocyte
population. Cell. Immunol. 35:34-42, 1978.
15.
Einhorn, L., Steinitz, M., Yefenof, E., Ernberg, I., Bakacs, T. and Klein, G.
Epstein-Barr Virus (EBV) receptors, complement receptors and EBV
infectability of different lymphocyte fractions of human peripheral blood. II.
EBV studies. Cell. Immunol. 35:43-48, 1978.
16.
Bakacs, T., Klein, E., Yefenof, E., Gergely, P. and Steinitz, M. Human blood
lymphocyte fractionation with special attention to their cytotoxic potential. Z.
Immun. Forsch. 154:121-134, 1978.
17.
Yefenof, E., Lundin, L. and Klein, G. Shedding of surface IgM from antibody
coated human lymphoma lines: Differences between EBV negative lines and
their virus converted sublines. Eur. J. Immunol. 8:190-193, 1978.
18.
Steinitz, M., Bakacs, T., Yefenof, E. and Klein, G. Inhibition of DNA
metabolism in human B lymphocytes by a substrain of EBV (P3HR-1): A
method for virus quantitation. Intervirology 10:125-131, 1978.
19.
Klein, G., Yefenof, E., Falk, K. and Westman, A. Relationship between
Epstein-Barr Virus (EBV) - production and the loss of the EBV
receptor/complement receptor complex in a series of sublines derived from
the same original Burkitt's lymphoma. Int. J. Cancer 21:522-560, 1978.
20.
Ber, R., Klein, G, Moar, M., Povey, S., Rosen, A., Westman, A., Yefenof, E.
and Zeuthen, J. Somatic cell hybrids between human lymphoma lines. IV.
Establishment and characterization of a P3HR-1/Daudi hybrid. Int. J. Cancer
21:707-719, 1978.
21.
Yefenof, E. Plasma membrane functions and dynamics of normal and
transformed lymphoid cells. Thesis. Tycho Wretman Press, Stockholm, 1978.
22.
Viallat, J., Svedmyr, E., Yefenof, E., Klein, G. and Weiland, O. Stimulation of
human peripheral blood lymphocytes by autologous EBV-infected B cells.
Cell. Immunol. 41:1-8, 1978.
23.
Karande, A., Yefenof, E., Fenyo, E.M. and Klein, G. Moloney lymphoma cells
express a polyprotein containing the gag gene-coded p15 and Moloney
leukemia virus-induced cell surface antigen (MCSA). Int. J. Cancer 23:508513, 1979.
24.
Yefenof, E. Epstein Barr Virus (EBV) and complement (C) interactions with
human lymphoid cells. In: Modern Trends in human leukemia III. (Eds. R.
Neth, R.C. Gallo, P.H. Hofschneider and K. Mannweiler), pp. 237-238,
Springer Verlag, Berlin, Heidelberg, New York, 1979.
25.
Dierich, M.P., Schultz, T., Yefenof, E. and Klein, G. Detection of proteolytic
(C3- cleaving) activity on mouse mastocytoma (p815) cells and other mouse
cell lines by formation of cell contact with C3-carrying mouse lymphocytes.
Eur. J. Immunol. 9:28-32, 1979.
26.
Polliack, A., Yefenof, E., Gamliel, H. and Klein, G. Burkitt's lymphoma cells:
Membrane properties and surface morphology as seen by scanning electron
microscopy. Leukemia Res. 3:217-225, 1979.
27.
Dierich, M.P., Schultz, T., Yefenof, E. and Klein, G. C3 activation proteases
of human lymphoblastoid cells superinfected with Epstein-Barr Virus. Cell.
Immunol. 51:168-172, 1980.
28.
Yefenof, E., Tchakirov, R. and Kedar, E. In vitro generation of cytotoxic
lymphocytes against radiation and radiation leukemia virus (RadLV) induced
tumors. I. Role of viral antigenicity. Cancer Immunol. Immunother. 8:171178, 1980.
29.
Yefenof, E. In vitro generation of cytotoxic lymphocytes against radiation and
radiation leukemia virus (RadLV) induced tumors. II. A radiation induced
thymoma generates cytotoxic response in syngeneic but not in allogeneic
lymphocytes. Immunology 41:99-106, 1980.
30.
Yefenof, E., Meidav, A. and Kedar, E. In vitro generation of cytotoxic
lymphocytes against radiation and radiation leukemia virus (RadLV) induced
tumors. III. Suppression of anti tumor immunity in vitro by lymphocytes of
mice undergoing RadLV induced leukemogenesis. J. Exp. Med. 152:14731483, 1980.
31.
Yefenof, E. Viruses and Cancer. "Ladaat", Science for Youth, 4: 10-13,
Weizmann Science Press of Israel, 1981 (Hebrew).
32.
Azar, Y., Eidelsztein, P., Yefenof, E., Chriqui, E., Katz-Gross, A., Kedar, E.
and Ben-Sasson, S.Z. Antigen specific murine T cell lymphomas: Functional
heterogenicity. Cellular Immunol. 65: 194-200, 1981.
33.
Yefenof, E., Azar, Y., Eidelsztein, P. and Ben-Sasson, S.Z. Antigen specific
murine T cell lymphomas. J. Immunol. 128: 625-628, 1982.
34.
Yefenof, E., Goldappel, M. and Ber, R. Nonimmunogenic radiation- induced
lymphoma: Immunity induction by a somatic cell hybrid. J. Nat. Cancer Inst.
68: 841-849, 1982.
35.
Yefenof, E. and Zilcha, D. High and low leukemogeneic variants of radiation
leukemia virus (RadLV) differ in ability to induce tumor specific immune
suppression. Int. J. Cancer 30: 355-359, 1982.
36.
Yefenof, E., Schwartz, S. and Katz-Gross, A.. Increased humoral and
cellular immunity in mice inoculated with allogeneic tumor cells attached to
microcarrier beads. Immunol. Letters 6: 39-43, 1983.
37.
Yefenof, E. and Ben-David, Y. Suppressor and reactive lymphocytes in
radiation leukemia virus (RadLV)-induced leukemogenesis. Cancer Immunol.
Immunother. 16: 48-52, 1983.
38.
Yefenof, E., Yron, I. and Klein, E. Complement-dependent cellular
cytotoxcity due to alternative pathway C3 activation by the target cell
membrane. Cell. Immunol. 87: 698-702, 1984.
39.
Yefenof, E., Ben-David, Y. and Kotler, M. High- and low- leukemogenic
variants of the radiation leukemia virus (RadLV): Immunogenic, suppressive
and genetic properties in relation to leukemogenic activity. Int. J. Cancer 34:
875-882, 1984.
40.
Yefenof, E., Klein, E. and Yron, I. Contribution of activated C3 to
lymphocyte-mediated target lysis: Complement-dependent cellular
cytotoxicity. Mol. Immunol. 21: 1211-1214, 1984.
41.
Yefenof, E. and McConnel, I. Interferon amplifies complement activation by
Burkitt's lymphoma cells. Nature 313: 684-686, 1985.
42.
Yefenof, E., Feinman, R. and Kedar, E. Antigen nonspecific activities in
culture supernatant of ovalbumin-specific cloned helper T lymphoma.
Immunobiology 169: 520-531, 1985.
43.
Ramos, O.F., Sarmay, G., Klein, E., Yefenof, E. and Gergely, J. Complement
dependent cellular cytotoxicity. Lymphoblastoid cell-lines that activate C3 and
express C3 receptors have elevated sensitivity to lymphocyte mediated lysis
in the presence of fresh human serum. Proc. Nat. Acad. Sci. (USA) 88: 57405744, 1985.
44.
Yefenof, E., Sanders, V.M., Snow, C.E., Noelle, R.J., Oliver, K.G., Uhr, S.W.
and Vitetta, E.S. Preparation and analysis of antigen specific memory B cells.
J. Immunol. 135: 3777-3784, 1985.
45.
Yefenof, E. and Ben-David, Y. Immunity and suppression in radiation and
RadLV induced leukemogenesis. Leukemia Res. 10; 797-801 1986.
46.
Klein, E., Ramos, O., Sarmay, G., Yefenof, E. and Gergely, J. Contribution of
activated C3 to lymphocyte mediated target lysis. Proc. 14th Int. Cong.
Chemother. 234-238, 1986.
47.
Yefenof, E., Sanders V.M., Uhr J.W. and Vitetta E.S. In vitro activation of
murine antigen specific memory B cells by a T dependent antigen. J.
Immunol. 137:85-90, 1986.
48.
Klein, E., Sarmay, G., Ramos, O.F., Yefenof, E. and Gergely, J. Contribution
of activated C3 to lymphocyte mediated cytolysis. Mol. Immunol. 23:12571262, 1986.
49.
Ben-David, Y., Kotler, M. and Yefenof, E. Leukemogenic, immunogenic and
genetic properties of a Thymotropic Radiation Leukemia virus. Int. J. Cancer
39:492-497, 1987.
50.
Myers, C.D., Sanders V.M., Yefenof, E., Oliver, K.G., Uhr, J.W. and Vitetta,
E.S. Purification and characterization of antigen binding virgin and memory B
cells. Methods in Enzymol. 150:316-325, 1987.
51.
Yefenof, E. and Klein, E. The third compotent of complement (C3) and its
contribution to the immune response. Harefua (Hebrew), 113:175-177, 1987.
52.
Ben-David, Y., Yefenof, E. and Kotler, M. Clonal analysis of Radiation
Leukemia Virus (RadLV) induced leukemic and preleukemic cells. Cancer
Res. 47:6590-6594, 1987.
53.
Klein, E., Ramos, O.F., Sarmay, G., Yefenof, E. and Gergely, J. Contribution
of C3 fragments to lymphocyte mediated lysis of CR2 carrying cells. In:
Lymphocyte Activation and Differentiation (J.L. Mani and J. Dornand, Eds),
Walter de Grayter & Co., Belin, New York, pp. 793-796, 1988.
54.
Bakacs, T., Totpal, K., Ringwald, G. and Yefenof, E. Comparison of
monocyte and complement mediated haemolysis of human A1 erythrocytes:
The relationship between antibody, target and effector concentrations in the
induction of lysis. J. Clin. Lab. Immunol. 25:53-58, 1988.
55.
Kai, C., Klein, E., Sarmay, G., Ramos, O., Yefenof, E. and Klein, G. Elevated
NK sensitivity of raji cells carrying acceptor bound C3 fragments. Cell.
Immunol. 113:227-234, 1988.
56.
Ramos, O.F., Kai, C., Yefenof, E. and Klein, E. The elevated natural killer
sensitivity of targets carrying surface attached C3 fragments require the
availability of the iC3b receptor (CR3) on the effectors. J. Immunol. 144:12391243, 1988.
57.
Yefenof, E., Ben-David, Y. and Kotler, M. Preleukemic cells induced by
RadLV are of an oligoclonal nature. Leukemia 2:97-101, 1988.
58.
Klein, E., Ramos, O.F., Sarmay, G., Yefenof, E. and Gergely, J. Lysis of CR2 carrying cells by natural killer cells and by activated T lymphocytes is
enhanced by C3 fragments. Mol. Immunol. 25:1063-1066, 1988.
59.
Ramos, O.F., Algarra, I., Sarmay, G., Yefenof, E., Gergely, J. and Klein, E.
Lymphocytes stimulated by allogeneic B cell lines cleave the third component
of complement and fix C3 fragments. Their nonspecific lytic capacity is
elevated against complement receptor type two (CR2) carrying targets. J.
Immunol. 142:217-223, 1989.
60.
Ramos, O.F., Patarroyo, M., Yefenof, E. and Klein, E. Requirement of
leukocytic cell adhesion molecules CD11a-c/CD18 in the enhanced NK lysis
of iC3b-opsonized targets. J. Immunol. l42:4l00-4l04, l989.
61.
Yefenof, E., Ramos, O.F., Nilsson, B. and Klein, E. Ligands of CR2 do not
interfere with C3 fragment fixation and enhanced NK sensitivity of Raji cells
treated with human serum. Immunol. Letters 2l:303-306, 1989.
62.
Sprecher, E., Giloh, H., Rachamim, E., Yefenof, E. and Becker, Y.
Cytofluorometric analysis of thymic interdigitating cells in normal and
irradiated C57BL/6 mice. Leukemia Res. 13:799-809, 1989.
63.
Ramos, O.F., Nilsson, B., Nilsson., K., Eggertsen, G., Yefenof, E. and Klein,
E. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b
fragments. Cell Immunol. 119:459-469, 1989.
64.
Yefenof, E., Benizri, R., Reiter, Y., Klein, E. and Fishelzon, Z. Potentiation of
NK cytotoxicity antibody - C3b/iC3b heteroconjugates. J. Immunol. 144:15381543, 1990.
65.
Yefenof, E., Zehavi-Feferman, R. and Guy, R. Control of primary and
secondary antibody responses by cytotoxic T lymphocytes specific for a
soluble antigen. Eur. J. Immunol. 20:1849-1853, 1990.
66.
Klein, E., Di-Renzo, L. and Yefenof, E. Contribution of CR3, CD11b/CD18 to
cytolysis by human NK cells. Mol. Immunol. 27:1343-1347, l990.
67.
Laskov, R., Ishay-Michaeli, R., Sharir, H., Yefenof, E. and Vlodavsky, I.
Production of heparanase by normal and neoplastic murine B-lymphocytes.
Int. J. Cancer 47:92-98, 1991.
68.
Di-Renzo, .L., Yefenof, E., and Klein, E. The function of human NK cells is
enhanced by beta-glucan, a ligand of CR3. Eur. J. Immunol. 21:1755-1758,
l99l.
69.
Naftalovich, S., Yefenof, E. and Eilam, E. Growth inhibitory and
chemotherapeutic effects of TFP and KTZ in murine T cell lymphomas.
Cancer Chemoth. Pharmac. 28:384-390, l99l.
71.
Yefenof, E., Asjo, B., and Klein, E. Alternative complement pathway
activation by HIV infected cells: C3 fixation does not lead to complement lysis
but enhances NK sensitivity. Int. Immunol. 3:395-401, 1991.
72.
Yefenof, E., Algarra, I., Ramos, O., and Klein, E. Activation and fixation of
serum C3 by human B cell lines is enhanced by Interferon gamma and Tumor
Necrosis Factor alfa. Complement and Inflamation 8:271-280, l99l.
73.
Messika, E., Gallily, R. and Yefenof, E. Radiation Leukemia Virus (RadLV)induced leukemogenesis is associated with an increased number and activity
of thymic macrophages. Int. J. Cancer 48:924-930, l991.
74.
Yefenof, E., Einat, E. and Klein, E. Potentiation of T cell immunity against
Radiation Leukemia Virus induced lymphoma by PSK. Cancer Immunol.
Immunother. 34:133-137, l99l.
75.
Yefenof, E., Epsztein, S. and Kotler, M. Quantitation, in vitro propagation,
and characterization of preleukemic cells induced by Radiation Leukemia
virus. Cancer Res. 51:2179-2184, 1991.
76.
Yefenof, E., Abboud, G., Epszteyn, S. and Vitetta, E.S. Treatment of
premalignancy: Prevention of lymphoma in radiation leukemia virusinoculated mice by cyclosporin A and immunotoxin. Proc. Natl. Acad. Sci.
(USA) 89:728-732, l992.
77.
Kuraya, M., Yefenof, E., Klein, G. and Klein, E. Expression of complement
regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their
role in sensitivity to human Serum-mediated lysis. Eur. J. Immunol. 22:18711876, 1992.
78.
Yefenof, E., Ela, C. Kotler, M. and Vitetta, E.S. Induction of IL-4 by the
Radiation Leukemia Virus (RadLV): Role in autocrine growth stimulation of
RadLV infected preleukemic cells. Int. J. Cancer 50:481-485, l992.
79.
Yefenof, E., Picker, L.J., Scheuermann, R.H., Tucker, T.F., Vitetta, E.S. and
Uhr, J.W. Cancer dormancy: Isolation and characterization of dormant
lymphoma cells. Proc. Natl. Acad. Sci. (USA) 30:1829-1833, 1993.
80.
Guy, R., Yefenof, E. and Zilberman, Y. Mitogenic activation of
phosphoinositide turnover and DNA synthesis in murine CD4+8+ thymocytes.
Immunol. Letters 36:251-260, 1993.
81.
Yefenof, E., Picker, L.J., Scheuermann, R.H., Vitetta, E.S. , Street, N.E.,
Tucker, T.F. and Uhr, J.W. Induction of B cell tumor dormancy by antiidiotypic antibodies. Current Opinion Immunol. 5:740-744, 1993.
82.
Kotler, M., Ruchlemer, R. Avni, O. and Yefenof, E. Radiation
Leukemogenesis: Quantitative relationship between preleukemic cells in the
thymus and lymphoma induction. Int. J. Cancer 56:761-765, 1994.
83.
Scheuermann, R. H., Racila, E., Tucker, T., Yefenof, E., Street, N.E., Vitetta,
E.S., Picker, L.J. and Uhr, J.W. Lyn tyrosine kinase signals cell cycle arrest
but not apoptosis in B lineage lymphoma cells. Proc. Natl. Acad. Sci. (USA),
91:4048-4052, 1994.
84.
Yefenof, E., Magyarlaki, T., Fenyo, E-M., Wahren, B. and Klein, E.
Alternative complement pathway activation by CD4+ cells of HIV infected
individuals: A possible role in AIDS pathogenesis. Int. Immunol. 6:1361-1366,
1994.
85.
Chaushu, S., Chaushu, G., Garfunkel, A.A., Slavin, S., Or, R. and Yefenof,
E. Salivary immunoglobulins in recipients of bone marrow grafts: I. A follow
up study. Bone Marrow Transpl. 14:871-876, 1994.
86.
Chaushu, S., Chaushu, G., Garfunkel, A.A., Slavin, S., Or, R. and Yefenof, E.
Salivary immunoglobulins in recipients of bone marrow grafts: II. Transient
secretion of donor derived salivary IgA following transplantation of T cell
depleted bone marrow. Bone Marrow Transpl. 14:925-928, 1994.
87.
Chaushu, G., Itzkovitz-Chaushu, S., Yefenof, E., Slavin, S., Or, R. and
Garfunkel, A.A. A longitudinal follow-up of saliva secretion in bone marrow
transplanted patients. Oral Surg. Pathol. 79:164-169, 1995.
88.
Yefenof, E. and Kotler, M. Radiation Leukemia Virus (RadLV) induced
leukemogenesis: A paradigm of preleukemia and its control by preventive
therapy. Adv. Cancer Res. 66:293-312, 1995.
89.
Racila, E., Scheuermann, R., Picker, L., Yefenof, E., Tucker, T., Chang, W.,
Marches, R., Street, N., Vitetta, E.S. and Uhr, J.R. Cancer dormancy:
Antibody as an agonist in inducing dormancy to a B cell lymphoma in SCID
mice. J. Exp. Med. 181:1539-1550, 1995.
90.
Messika, E.J., Yefenof, E., Gallily, R., Avni, O. and Baniyash, M.
Identification and characterization of a novel protein associated with
macrophage complement receptor 3. J. Immunol. 154:6563-6570, 1995.
91.
Yefenof, E. Cellular, biochemical and molecular analysis of tumor dormancy.
In: Cellular microbiology and pathology. Lombardo Institute of Science,
Milano 5:86-92, 1995.
92.
Avni, O., Yefenof, E. and Kotler, M. Clonal dominance of RadLV-induced
lymphomas. Leukemia Res. 19:971-976, 1995.
93.
Jarrah, S., Eran, M, Freier, S, and Yefenof, E. Cholecystokinin-octapeptide
(CCK-OP) and substance P (SP) influence immune response to cholera toxin
in live animals. Adv. Exp. Med. Biol. 371:533-536, 1995.
94.
Yefenof, E., Gafanovitch, I., Oron, E., Bar, M. and Klein, E. Prophylactic
intervention in radiation-leukemia-virus-induced murine lymphoma by the
biological response modifier polysaccharide K. Cancer Immunol.
Immunother. 41:389-396. 1995.
95.
Chaushu, G., Chaushu, S., Slavin, S., Or, R., Garfunkel, A.A. and Yefenof, E.
Salivary immunoglobulins in recipients of bone marrow grafts: III. A
Longtitudinal follow-up of CMV specific antibodies. Bone Marrow Transpl.
17:237-241, 1996.
96.
Yefenof, E. and Scheuermann, R. Editors. Premalignancy and Tumor
Dormancy. Chapman & Hall, Springer Verlag, 1996.
97.
Scheuermann, R. and Yefenof, E. Common and distinct characteristics of
premalignancy and tumor dormancy. In: Premalignancy and tumor dormancy
(E. Yefenof and R. Scheuermann, Editors), pp. 1-5, Chapman & Hall,
Springer Verlag, 1996.
98.
Zilberman, Y., Yefenof, E., Oron, E., Dorogin, A. and Guy, R. T cell receptorindependent apoptosis of thymocyte clones induced by a thymic epithelial cell
line is mediated by steroids. Cell. Immunol. 170:78-84, 1996.
99.
Guy, R., Gafanovich, I., Rosenheimer, N., Oron, E., Yefenof, E., and
Zilberman, Y. MHC non-restricted, CD95 independent apoptosis of immature
thymocytes induced by thymic epithelial cells. Cell Death Different. 3:431438, 1996.
100.
Yefenof, E. A Murine Lymphoma Model of Tumor Dormancy. Pediat. Res.
41:750, 1997.
101.
Epsztein, S., Vitetta, E.S. and Yefenof, E. Prophylactic intervention in
RadLV-induced lymphomagenesis with an anti-IL-4 monoclonal antibody. J.
Immunother. 20:287-291, 1997.
102.
Yefenof, E. Apoptosis in the Immune System and Cancer: Common
Denominators and Bilateral Implications. Biotherapy 12:1-5, 1998.
103.
Avni, O., Pur, Z., Yefenof, E. and Baniyash, M. Complement receptor 3
(CD11b/CD18) of macrophages is associated with Galectin-1. J. Immunol.
160:6151-6158, 1998.
104.
Zilberman, Y., Dorogin, A., Oron, E., Guy, R. and Yefenof, E. The
involvement of calcium ions and protein kinase C in thymic epithelial cell line
induced apoptosis of T lymphoma clones. Immunol. Letters. 67:95-104,
1999.
105.
Yefenof, E. Murine models of thymic lymphomas: premalignant scenarios
amenable to prophylactic therapy. Adv. Immunol. 73:511-538, 1999.
106.
Rosenheimer, N., Haupt, Y., Yefenof, E., Zilberman, Y. and Guy, R. P53 and
thymic death by neglect: thymic epithelial cell-induced apoptosis of CD4+8+
thymocytes is P53 independent. Cell Death Different. 7:241-249, 2000.
107.
Clinchy, B., Gazdar, A., Rabinovsky, R., Yefenof, E., Gordon, B. and Vitetta,
E.S. The growth and metastasis of human, HER-2/neu-overexpressing tumor
cell lines in male scid mice. Breast Cancer Res. and Treat. 61:207-228,
2000.
108.
Yefenof, E. Complement receptor 3 (CR3): a public transducer of innate
immunity signals in macrophages. Adv. Exp. Med. Biol. 479:15-25, 2000.
109.
Yefenof, E., guest editor, Tumor dormancy. Seminars in Cancer Biology,
Academic Press. 2001.
110.
Yefenof, E. Cancer dormancy: from observation to investigation and onto
clinical intervention. In: Cancer dormancy. Seminars in cancer biology.
11:269-272, 2001.
111.
Yefenof, E. Role of CR3 in innate immunity. Molecular Immunol. 38:130,
2001.
112.
Honigman, A., Zeira, E., Ohana, P., Abramovitz, R., Tavor, E., Bar, I.,
Zilberman, Y., Rabinovsky, R., Yefenof, E., Joseph, A., Laster, M. and Galun,
E. Imaging transgene expression in live animals. Molecular Therapy. 4:239299, 2001.
113.
Chaushu, S., Yefenof, E., Becker, A., Shapira, J. and Chaushu, G. Severe
impariment of secretory Ig production in partoid saliva of dwon syndrome
idividuals. J. Dent. Res. 81:308-312, 2002.
114.
Chaushu, S., Yefenof, E., Becker, A., Shapira, J., Gat, H. and Chaushu, G.
A link between partoid salivary Ig level and recurrent respiratory infections in
young down’s syndrome patients. Oral Microbiol. Immunol. 17:172-176, 2002.
115.
Guy, R., Naor, D., Dorogin, A., Zilberman, Y., and Yefenof, E. CD44 costimulates thymic lymphomas and T cell hybridomas. Cell. Immunol. 216, 8287, 2002.
116.
Rabinovsky, R., Zeira, E., Galun, E., Uhr, J.W., Vitetta, E.S., and Yefenof, E.
Growth inhibition of prostate adenocarcinoma in vitro and in vivo by anti HER2 immunotoxins. In: Tumor Microenvironment Progression, Therapy and
Prevention (Isaac P. Witz, Ed), Monduzzi International Proceedings, pp. 151156, 2003.
117.
Zilberman, Y., Dorogin, A., Zafrir, E., Ovadia, H., Guy, R., Vogt-Sionov, R.
and Yefenof, E. Modulated expression of Glyco-cortiocoid receptor in thymic
lymphomas: Implications for "death by neglect." Cell. Immunol. 227:12-23,
2004.
118.
Sionov, R., Zilberman, Y., Cohen, O., Kfir, S. and Yefenof, E. Role of
mitochondrial glucocorticoid receptor in glycocorticoid-induced apoptosis. J.
Exp. Med. 203: 189-201, 2006.
119.
Sionov, R., Kfir, S., Cohen, O., Zilberman, Y. and Yefenof E. Glucocorticoid
induced apoptosis revisited: A novel role for glucocorticoid receptor
translocation to the mitochondria. Cell Cycle, 5:1017-1026, 2006.
120.
Zigmond, M. Stabholz, A., Shapiro, J., Bachrach G., Chaushu G., Becker A.,
Yefenof E., Merrick J., and Chaushu, S. The outocome of a preventive dental
care programme on the prevalence of localized aggressive periodontitis in
Down’s Syndrome individuals, Normal. J. Dental Res. 50: (Pt 7) 492-500,
2006.
121.
Bachrach, G., Chaushu, G., Zigmond, M., Yefenof, E., Stabholz, A. Shapiro,
J. Merrick, J., and Chaushu, S. Salivary LL-37 Secretion in Down’s Syndrome
is Normal. J Dental Res. 853: 933-936, 2006.
122.
Cervi, D., Shaked, Y., Haeri, M., Usenko, T., Lee, C., Hincklin, D., Naagy, A.,
Kerbel, R.S., Yefenof, E., Ben-David, Y. Enhanced Natural Killing and
Erythropoietic Activity in VEGF Overexpressing Mice Delays FMuLV Induced
Leukemogenesis. Blood, 109: 2139-46,2007.
123.
Rabinovsky, R., Uhr, J.W., Vitetta, E.S., and Yefenof, E. Cancer Dormancy:
Lessons from a B Cell Lymphoma and Prostate Adenocarcinoma. Adv.
Cancer Res. 97: 189-202, 2007.
124.
Kfir, S., Sionov, R.V., Zafrir, E., Zilberman, Y., and Yefenof, E. Staurosporine
sensitizes T Lymphoma cells to glucocortioid induced apoptosis: Role of
Nur-77 and BCL-2. Cell Cycle 6:3086-3096, 2007.
125.
Mizrachi, S., Mandelboim, O., Yefenof, E., Atal, D., Gross, M., Stern, N.,
Gazit, R. and Chaushu S. Phenotypic and Functional Characterization of
Adenoidal NK Cells. J. Leukoc. Biol. 82:1095-1105, 2007.
126.
Chaushu, S., Chaushu, G., Zigmond, M., Yefenof, E., Stabholz, A., Shapira,
J., Merrick, J. and Bachrach, G., Age dependent deficiency in saliva and
salivary antibodies secretion in Down’s syndrome. Arch. Oral Biol. 52:10881096, 2007.
127.
Innate and adaptive immunity at the tumor microenvironment. Yefenof, E.,
editor, Springer Science, 2008.
128.
Yefenof, E. Tumor Microenvironment under the magnifying glass: A new
challenge to cancer immunologists, In: Innate and adaptive immunity in the
tumor microenvironment. Springer Science, 2008.
129.
Sionov, R.V., Spokoini, R., Kfir, S., Cohen, O. and Yefenof, E. Mechanisms
regulating the susceptibility of hematopoietic malignancies to glucocorticoid
induced apoptosis. Adv. Cancer Res. 101C:127-248, 2008.
Izhak, L., Wildbaum, G., Zohar, Y., Anunu, R., Klapper, L., Elkeles, A.,
Seagal, J., Yefenof, E., Ayalon-Soffer, M. And Karin, N. A novel recombinant
fusion protein eccoding a 20-amino acid residue of the third extracellular (E3)
domain of CCR2 neutralizes the biological activity of CCL2. J. Immunol.
183:732-739, 2009.
Cohen, O., Kfir-Erenfeld, S., Spokoini, R., Zilberman, Y., Yefenof, E. and
Vogt-Sionov, R. Nitric Oxide cooperates with Glucocorticoids in Thymic
Epithelial Cell-mediated apoptosis of double positive thymocytes. Int.
Immunol. 21:1113-1123, 2009.
Spokoini, R., Kfir-Erenfeld, S., Vogt-Sionov, R. and Yefenof, E. Glycogen
synthase kinase-3 plays a central role in mediating glucocorticoid-induced
apoptosis. Mol Endocrinol. 24:1136-1150, 2010.
Kfir-Erenfeld, S., Sionov, R., Spokoini, R., Cohen, O. and Yefenof, E. Protein
kinase networks regulating gluco-corticoid induced apoptosis of hemopoietic
cancer cells: Fundmental and practical aspects. Leukemia & Lymphoma,
51:1968-2005, 2010.
Eisenberg, G., Machlenkin, A., Frankenburg, S., Mansura, A., Pitcovski, J.,
Yefenof, E., Peretz, T. and Lotem, M. Transcutaneous immunization with
hydrophilic recombinant gp100 protein induces antigen-specific cellular
immune response. Cell. Immunol. 266:98-103, 2010.
Sionov, R.V., Spokoini, R., Kfir-Erenfeld, S. and Yefenof, E. A Role for Bcl-2
in Notch1-Dependent Transcription in Thymic Lymphoma Cells. Advan.
Hematol. In press 2011.
Trogocytosis is a gateway to characterize functional diversity in melanomaspecific CD8+ T cell clones. Uzana, R. Eisenberg, G., Sagi, Y., Frankenburg,
S., Amariglio, N., Yefenof, E., Peretz, T., Machlenkin, A. and Lotem, M.
Submitted, 2011.
130.
131.
132.
133.
134.
135.
136.